EntreMed (ENMD) Initiates ENMD-2076 Phase 2
EntreMed, Inc. (Nasdaq: ENMD) announced the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adaptimmune Therapeutics (ADAP) Announces NY-ESO-1-T Granted F DA Breakthrough Therapy Designation
- Axovant Sciences Ltd. (AXON) Reports Q3 Loss Per Share of 64c
- Prothena Corp. (PRTA) Announces Data from Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in Journal of Clinical Oncology
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!